Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
Post-Transplant Gene Mutations Predict Risk for MDS Progression
Sequencing bone marrow samples early after patients with myelodysplastic syndromes (MDS) have undergone allogeneic hematopoietic cell transplantation (AHCT) could help identify patients who are...
Rivaroxaban Fails to Prevent VTE and VTE-Related Mortality After Hospital Discharge
Patients hospitalized for an acute medical illness are at an increased risk for developing venous thromboembolism (VTE) in the six weeks after discharge, but...
Rituximab Plus Lenalidomide Noninferior to Chemotherapy in Treatment-Naïve Follicular Lymphoma
Treatment with the chemotherapy-free combination of rituximab and the immunomodulatory agent lenalidomide (R2) was noninferior to the combination of rituximab and chemotherapy (R-chemo) in...
Phase I Trial Shows Activity of Single-Agent Ivosidenib in IDH1-Mutated AML
Ivosidenib was safe and associated with remissions, transfusion independence, and molecular remissions in patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML), according...
Oral L-Glutamine Powder Lowers Frequency of Sickle Cell–Related Pain Episodes
Oral L-glutamine powder, with or without hydroxyurea, reduced the number of pain events experienced by children and adults with sickle cell disease (SCD), compared...
Tumor Site, D-Dimer Markers Predict VTE Risk in Patients With Cancer
Venous thromboembolism (VTE) is a common complication of cancer, with the risk of developing VTE varying greatly depending on several patient and disease factors....
Can a Liquid Biopsy Predict Outcomes in DLBCL?
In a study of patients with diffuse large B-cell lymphoma (DLBCL), levels of pretreatment circulating tumor DNA (ctDNA) and molecular responses were independent predictors...
Study Reveals Platelet Counts Decrease for All Women During Pregnancy
Gestational thrombocytopenia (defined as a platelet count <150,000/mm3 during uncomplicated pregnancy) has been recognized for more than 25 years, but the course of platelet...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
